Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Double-Blind, Controlled Trial to Assess the Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Subjects Aged Between 2 and <18 Years and Living in Dengue Endemic Countries in Asia and Latin America

Next Previous
X
Search
Trial Profile

A Phase II, Double-Blind, Controlled Trial to Assess the Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Subjects Aged Between 2 and <18 Years and Living in Dengue Endemic Countries in Asia and Latin America

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 04 Feb 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dengue tetravalent vaccine Takeda (Primary)
  • Indications Dengue
  • Focus Pharmacodynamics
  • Sponsors Takeda

    • Most Recent Events

    • 22 Jan 2022 Results published in the Vaccine
    • 03 Feb 2021 Results assessing polyclonal antibody avidity to all four DENV serotypes using sera from two phase 2 trials (DEN-203 and DEN-204) published in the Journal of Infectious Diseases
    • 23 Mar 2020 Results assessing Safety and immunogenicity of a tetravalent dengue vaccine in children, published in the Internet Document

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top